GlassScriptPhysician profile
Vincent Hsu
NPI 1033152624
$2,095.29
in general payments reported to CMS, 2019-2025
11 companies · $636 in 2025
The $636 reported for 2025 was more than what 76% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.07 · 2020: $280 · 2021: $124 · 2022: $288 · 2023: $228 · 2024: $504 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $856.46 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $291.79 | 2020-2022 | |
| Coopervision INC. | $259.93 | 2022-2025 | Misight Contact Lens, Clariti Contact Lens |
| Abbvie INC. | $193.85 | 2022-2025 | |
| Alcon Vision LLC | $159.17 | 2023-2024 | Rocklatan, Simbrinza, Rhopressa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $139.64 | 2020-2021 | |
| Oyster Point Pharma, INC. | $70.58 | 2023-2024 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $59.81 | 2021-2022 | |
| Harrow Eye, LLC | $28.99 | 2024 | Vevye |
| Novartis Pharmaceuticals Corporation | $22.70 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.